PSADT Predicts Mortality

Share this content:
Among men who experience PSA recurrence following radical prostatectomy (RP) for prostate cancer, a PSA doubling time (PSADT) of less than nine months at the time of recurrence is associated with a significantly increased risk of death, according to a study.

Compared with men whose PSADT was nine months or more, those with a PSADT less than three months had a nearly 10-fold greater risk of all-cause mortality; a PSADT of 3-8.9 months was associated with a 2.3 times increased risk.

The study, led by Stephen J. Freedland, MD, of the Duke Prostate Center at Duke University Medical Center in Durham, N.C., included 360 men who underwent RP between 1988 and 2008 at multiple Veterans Affairs medical centers nationwide within the SEARCH database.

The cohort was older and more racially diverse than populations examined in some previous studies of the association between PSADT and mortality, but confirm the earlier studies regarding the importance of PSADT as a predictor of overall mortality.

You must be a registered member of Renal and Urology News to post a comment.

Sign up for free e-Newsletters